Overview

S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers

Status:
Recruiting

Trial end date:
2025-07-01

Target enrollment:

Participant gender:

Summary

The purpose of the stuty is to investigate the safety, tolerability, and preliminary anti-neoplastic activity of S095029 alone and in combination with Sym021 in patients with advanced solid tumor malignancies followed by an expansion phase of triple combinations.

Phase:

Phase 1

Details

Lead Sponsor:

Institut de Recherches Internationales Servier

Collaborator:

ADIR, a Servier Group company